Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDACTINOMYCIN (dactinomycin) by Recordati is nucleic acid synthesis inhibitors [moa]. Approved for part of a multi-phase, combination chemotherapy regimen, nonseminomatous testicular cancer and 6 more indications. First approved in 2020.
Drug data last refreshed 18h ago
Nucleic Acid Synthesis Inhibitors
Actinomycin
Worked on DACTINOMYCIN at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo